Notes from the Field: Syndromic Surveillance Used To Monitor Emergency Department Visits During a Synthetic Cannabinoid Overdose Outbreak — Connecticut, August 2018

Sydney A. Jones, PhD1,2; Kristen Soto, MPH2; Erin Grogan, MS2; Alexander Senetcky, MPH2; Susan Logan, MS, MPH2; Matthew Cartter, MD2 (View author affiliations)

View suggested citation
Article Metrics
Altmetric:
Citations:
Views:

Views equals page views plus PDF downloads

Related Materials

On the morning of August 15, 2018, the Connecticut Department of Public Health (CTDPH) learned from media reports about multiple persons found unresponsive in a city park in New Haven County after using synthetic cannabinoids (SCs), manmade psychoactive substances that can cause unpredictable and sometimes severe health effects. Prevalence of acute SC poisonings has increased in the United States in recent years (1). Syndromic surveillance data collected in near real-time have been used to track outbreaks of illness and to improve public health authorities’ situational awareness about trends in suspected drug overdoses (2). CTDPH monitored syndromic surveillance data from emergency department (ED) visit records to identify the magnitude of the SC overdose outbreak and provide situational awareness during the outbreak to state and local health departments.

Since January 2018, CTDPH syndromic surveillance system has collected data on ED visits from all 38 EDs in Connecticut by using the EpiCenter system (Health Monitoring Systems, Inc.). Using Health Level Seven messaging,* EDs transfer visit data (e.g., patient sex, age, ZIP Code of residence, chief complaint, and triage notes) to EpiCenter upon patient registration and discharge in near real-time (i.e., <5 minutes).

Within 20 minutes of receiving the first media report, CTDPH developed an ad hoc syndrome definition to identify ED visits for suspected SC overdoses by querying EpiCenter. The syndrome definition was derived from keywords in the chief complaint, selected in an iterative process from terms in media reports and ED visit record reviews. Initial keywords included terms for SCs (e.g., “K2,” “spice,” or “weed”) and later refined to include terms for location (e.g., “green,” “bench,” or “park”). By midday on August 15, a total of 25 suspected outbreak-related ED visits had been identified; by 5:00 p.m. on August 16, the number had increased to 55, all in New Haven County. CTDPH leadership and the local health department were updated with these data via periodic e-mails. The outbreak response ended on August 17. The U.S. Department of Justice Drug Enforcement Administration determined that SCs implicated in this outbreak contained AMB-FUBINACA, an ultrapotent SC with strong depressant effects (3,4).

On August 20, CTDPH further refined the syndromic case definition to include keywords in either chief complaint or triage notes to retrospectively identify outbreak-related ED visits during August 15–16 that were missed by near real-time chief complaint analysis. For this retrospective analysis, an outbreak-related ED visit was defined as an ED visit in New Haven County during August 15–16 with SC- or location-related keywords in the chief complaint or triage notes. Among 2,086 ED visits in New Haven County during August 15–16, a total of 72 met the updated outbreak-related SC overdose syndrome definition. Those 72 ED visits comprised 53 unique patients, 12 of whom returned to the ED up to five times for SC overdose visits, indicating possible reexposure to SC containing AMB-FUBINACA. Median patient age was 43 years (interquartile range = 35–51 years), and 41 (77%) patients were male. Among 63 ED visits with discharge disposition data, patients were discharged after 57 ED visits (90%), and six (10%) left without being seen; none died.

Near real-time syndromic surveillance data provided timely situational awareness to public health departments about the approximate magnitude of the outbreak; a follow-up analysis allowed the extent of the SC outbreak to be characterized and confirmed that the outbreak had ended. After this outbreak, CTDPH created additional substance- and location-specific overdose syndrome definitions to help detect future drug overdose–related events and built an exploratory data analysis dashboard to facilitate near real-time data analysis. This outbreak also led to development of CTDPH standard operating guidelines for information sharing and resource allocation with response partners during overdose-related events. CTDPH shared best practices and the syndrome definition from this investigation with the National Syndromic Surveillance Program Community of Practice. Syndromic surveillance has the potential to be an important tool to provide public health officials with situational awareness of substance use–related morbidity.

Acknowledgment

Kris Bisgard, Center for Surveillance, Epidemiology, and Laboratory Services, CDC.

Corresponding author: Sydney A. Jones, okn7@cdc.gov, 860-509-7995.


1Epidemic Intelligence Service, Division of Scientific Education and Professional Development, Center for Surveillance, Epidemiology, and Laboratory Services, CDC; 2Connecticut Department of Public Health.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.


* Health Level Seven is a nationally recognized standard for electronic data exchange between systems housing health care data, which enables two-way exchange of information using a standardized vocabulary and syntax. https://www.cdc.gov/nssp/documents/guides/syndrsurvmessagguide2_messagingguide_phn.pdfpdf icon.

The National Syndromic Surveillance Program Community of Practice is a collaboration among CDC, federal partners, state and local health departments, academic institutions, and private sector partners. https://www.cdc.gov/nssp/overview.html.

References

  1. Riederer AM, Campleman SL, Carlson RG, et al.; Toxicology Investigators Consortium. Acute poisonings from synthetic cannabinoids—50 U.S. Toxicology Investigators Consortium registry sites, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:692–5. CrossRefexternal icon PubMedexternal icon
  2. Vivolo-Kantor AM, Seth P, Gladden RM, et al. Vital signs: trends in emergency department visits for suspected opioid overdoses—United States, July 2016–September 2017. MMWR Morb Mortal Wkly Rep 2018;67:279–85. CrossRefexternal icon PubMedexternal icon
  3. Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 2017;376:235–42. CrossRefexternal icon PubMedexternal icon
  4. Drug and Chemical Evaluation Section. FUB-AMB (AMB-FUBINACA; MMB-FUBINACA). Springfield, VA: US Department of Justice, Drug Enforcement Administration; 2019. https://www.deadiversion.usdoj.gov/drug_chem_info/FUB-AMB.pdfpdf iconexternal icon

Suggested citation for this article: Jones SA, Soto K, Grogan E, Senetcky A, Logan S, Cartter M. Notes from the Field: Syndromic Surveillance Used To Monitor Emergency Department Visits During a Synthetic Cannabinoid Overdose Outbreak — Connecticut, August 2018. MMWR Morb Mortal Wkly Rep 2020;69:220–221. DOI: http://dx.doi.org/10.15585/mmwr.mm6908a4external icon.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

View Page In:pdf icon PDF [68K]
Page last reviewed: February 27, 2020